IMT Header

Cambridge Healthtech Institute’s 2nd Annual
Target Discovery for T Cell Therapy
Current and Emerging Targets for CAR, TCR, and TIL
August 27-28


Current targets for adoptive T cell therapies are limited and challenging. As a result, increased discovery efforts have been launched to continue advancing the field. At Cambridge Healthtech Institute’s Second Annual Target Discovery for T Cell Therapy, leaders from academia and industry will come together to actively engage in discovery and translation of novel targets for T cell therapy. Experts will share strategies around T cell receptors (TCR) and tumor infiltrating lymphocytes (TIL), and special attention will be given to chimeric antigen receptors (CAR). Emphasis will also be placed on discovering new targets and novel classes of targets expressed on the cell membrane and inside the cell, mainly with tumor-specific and mutated antigens. Overall, this event provides a comprehensive look at the current challenges and existing opportunities in T cell therapy target discovery.

CHIMERIC ANTIGEN RECEPTORS  

KEYNOTE PRESENTATION: Enhancing the IQ of CAR T Cells

Michael C. Jensen, M.D., Professor, Pediatrics, University of Washington School of Medicine; Director,
Ben Towne Center for Childhood Cancer Research/Seattle Children's Research Institute; Joint Member, Program in Immunology, Fred Hutchinson Cancer Research Center

Next-Generation Chimeric Antigen Receptor (CAR) T Cell Therapies

Kevin M. Slawin, M.D., CMO & CTO, Bellicum Pharmaceuticals, Inc.

CAR T Cell Therapy: Target Antigen Discovery and Clinical Translation

Richard A. Morgan, Ph.D., Vice President, Immunotherapy, Bluebird Bio

Durable Clinical Responses without Persisting CAR T Cells in Circulation or Protracted On-Target Toxicity

Adrian Bot, M.D., Ph.D., Vice President, Translational Medicine, Kite Pharma, Inc.

PANEL: Characterizing T Cell Therapies in the Clinic

Moderator: Adrian Bot, M.D., Ph.D., Vice President, Translational Medicine, Kite Pharma, Inc.


T CELL RECEPTOR TARGETS AND PRODUCTS 

Session Speakers to be Announced


TUMOR INFILTRATING LYMPHOCYTES  

Session Speakers to be Announced


PERSONALIZED IMMUNOTHERAPY APPROACHES  

Engaging Macrophages as Effectors of Cancer Immunotherapy

Kipp A. Weiskopf, Ph.D., Research Scientist, Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine

Developing and Implementing T Cell Therapies for Tumors

Laurence J.N. Cooper, M.D., Ph.D., Grant Taylor, W.W. Sutow and Margaret Sullivan Distinguished Professor in Pediatrics, MDACC Section Chief, Cell Therapy, Children’s Cancer Hospital, Division of Pediatrics (Unit 907); Associate Director, CCIR, Director, Immunology Laboratory of Physician Scientists, Department of Immunology, MD Anderson Cancer Center

Discovery of Prostate Cancer-Reactive T Cell Receptors (TCR) for TCR Gene Therapy

Michael Bethune, Ph.D., Postdoctoral Scholar, Biology & Biological Engineering, Caltech


For more details on the conference, please contact:
Samantha Lewis
Conference Producer
Cambridge Healthtech Institute
T: (+1) 781-972-5461
E: slewis@healthtech.com  

For exhibit & sponsorship opportunities, please contact:
Katelin Fitzgerald
Sr. Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5458
E: kfitzgerald@healthtech.com